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Introduction
CCK‒8 is the major circulating form of cholecystokinin.1 It is 
extensively found in the gastrointestinal tract and as a neuropeptide, 
it is widespread in the nervous system.2 Cholecystokinin, CCK, was 
originally identified to cause contractions of the gallbladder,3 later it 
was discovered as pancreozymin, triggering the release of pancreatic 
enzymes. In the end, after controversial studies, it was confirmed 
that cholecystokinin and pancreozymin are identical peptides.4 
Cholecystokinin and its receptor has been extensively investigated 
as potential drug target.5 CCK‒agonists and CCK‒antagonists,6 
have been clinically evaluated as therapeutics. In particular, CCK 
acted as growth factor in certain forms of cancer.7 Cholecystokinin 
caused proliferation in colon‒and pancreatic cancer cell lines and 
therefore, CCK‒antagonists were studied as growth factor inhibitors 
in these CCK sensitive cancers. According to the role of CCK as a 
neurotransmitter, CCK antagonists were investigated as anxiolytics,8 
in the treatment of schizophrenia and satiety.9,10 Asperlicin was the 
first non‒peptidal CCK antagonist isolated from nature.11 The original 
lead structure was simplified by Merck and a fully synthetic antagonist 
Devazepide, was developed.12,13 This simplified antagonist was a 
potent and CCK1 selective cholecystokinin antagonist, containing a 
1,4‒benzodiazepine template and an indole moiety. Proglumide was 
the first glutamic acid derivative, which was marketed as Milid for 
the treatment of ulcer. Lorglumide, was derived from proglumide, 
Figure 1 and is now a common experimental CCK1 receptor standard. 
The replacement of the indolyl amide group in devazepide by a urea 
linkage resulted in Merck’s CCK2 selective antagonist L‒365, 260. 
Further SAR optimization by Zeria from L‒365, 260 towards Z‒360 
led to a CCK2–gastrin receptor antagonist with improved selectivity 
and bioavailability, which progressed into a phase 2 trial for pancreatic 
cancer.14‒18 The 1,4‒benzodiazepine structure was replaced by a non‒
chiral pyrazol template in our early discovery programmes. A pyrazol, 
containing an indole carboxylic acid and a phenyl urea moiety, 
showed excellent anxiolytic and antidepressant properties in mice. 
Later, the 1,4‒benzodiazepine template was varied by a combinatorial 
solid phase synthesis and a simple n‒propyl derivative was found the 
best CCK antagonist. Key in our recent search, was the low molecular 
weight <350, an optimum logp value about 3 and a restricted polar 
surface area of less than 100A2, thus, providing us with molecules of 
a high membrane penetration. Aim of the drug discovery programme, 
initiated by PNB Vesper Life Sciences, was to systematically design 
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Abstract
Background: Cholecystokinin and gastrin are endocrine growths factors for certain tumours 
and CCK1R and CCK2R receptors are ideal molecular targets for novel smart chemo‒
therapeutics with a beneficial overall profile due to their anxiolytic and antidepressant 
properties. Lung cancers are fuelled by gastrin and therefore, selective gastrin (CCK2R) 
antagonists are ideal experimental drug candidates.
Objective: Synthesis and evaluation of novel CCK antagonists, most preferred CCK2 /
gastrin selective for the treatment of lung cancers.
Methods: A fast and efficient synthesis of hydroxy‒pyrrolones in 2 steps from renewable 
biomass was performed. After initial radiolabelled receptor binding studies with hot 
CCK8, subsequent in vitro evaluation with isolated duodenum preparations confirmed 
CCK antagonism. Cell based studies using the MTT assay provided a candidate for in 
vivo xenograft models with nude mice. Rational drug design was supported by molecular 
modelling experiments.
Results: Potent and selective CCK antagonists were prepared as stable crystalline materials 
in high yields. Gastrin antagonists were in vitro active on isolated tissue preparations 
and inhibited breast, colon and lung cancer cell lines in vitro with IC
50
 to 45nM for the 
privileged hydroxyl‒pyrrolone lead structure in the MTT assay for human cancer cell lines. 
PNB‒101, a fluorinated 5‒hydroxy‒5‒aryl‒pyrrol‒2‒one, gave up to 80% inhibition of 
tumour growths by oral administration in athymic mice transplanted with the human lung 
cancer cell line H727. 
Conclusion: PNB‒101 is a potential chemotherapeutic agent for CCK‒gastrin related 
cancers and entered preclinical development.
Keywords: cholecystokinin, pancreatic enzymes, proliferation, pancreatic cancer, 
anxiolytics, devazepide
MOJ Drug Design Development & Therapy
Research Article Open Access
N‒substituted 5‒hydroxy‒pyrrol‒2‒ones based cholecystokinin‒2 antagonists as experimental 
anticancer agents for the treatment of lung cancer
181
Copyright:
©2018 Lattmann et al.
Citation: Lattmann E, Russell ST, Singh M, et al. N‒substituted 5‒hydroxy‒pyrrol‒2‒ones based cholecystokinin‒2 antagonists as experimental anticancer 
agents for the treatment of lung cancer. MOJ Drug Des Develop Ther. 2018;2(4):180‒189. DOI: 10.15406/mojddt.2018.02.00045
from the 2(5H)‒furanone scaffold a hydroxyl‒pyrrolone scaffold 
with ligands for both CCK1 and CCK2 pathways. Initial results for 
CCK antagonists of the pyrrolone scaffold were communicated in the 
area of cancer therapeutics and inflammation. Here, a full biological 
evaluation of the PNB‒cancer molecules towards PNB‒101, a potent 
and selective fluorinated gastrin antagonist will be reported in detail 
with respect to the anti‒neoplastic properties of the molecule, in 
particular for lung cancer.19‒27
Figure 1 Cholecystokinin antagonists: Substituted 5‒hydroxy‒ pyrrol‒2‒ones as experimental anticancer agents.
Materials and methods
Synthesis
The chemicals were obtained from standard supplies as outlined 
in, NMR spectra were calibrated with TMS and the melting points 
were uncorrected.
Preparation of stage 1 intermediates 
Synthesis of 3,4‒dichloro‒5‒phenyl‒5H‒furan‒2‒one, 
lactone A
Granulated aluminium chloride (20g, 0.15mol) was added slowly 
to a mixture of mucochloric acid (16.9g, 0.1mol) and arene (250ml). 
The reaction mixture was stirred overnight. It was then poured into 
a mixture of 100g ice and 32ml concentrated hydrochloric acid. The 
organic layer was separated and washed with 3x100ml water. The 
combined organic layers were dried over magnesium sulphate and the 
solvent was removed under vacuum. The oily residue was crystallized 
from n‒hexane.
Yield=70%; mp: 78‒79oC;
 
MS (APCI(+)): (M+), 230/232 (M+1)
m/z; 1HNMR (CDCl3) 250MHz: δ= 7.22‒7.51 (m, 5H), 5.81 (s, 1H); 
13CNMR (CDCl3):165.3, 152.2, 139.8, 130.5, 129.3, 128.5, 127.4, 
127.2, 121.2, 83.5; IR (KBr‒disc) δmax: 3445, 3074, 3035, 2959, 
2056, 1768, 1630, 1499, 1457 1294, 1224, 1028, 910, 772, 705cm‒1
3,4‒Dichloro‒5‒(4‒chloro‒phenyl)‒5H‒furan‒2‒one, 
lactone B
Yield=69% mp: 76‒78oC; MS (APCI(+)): 262/263/265 (M+)m/z; 
1HNMR (CDCl3) 250MHz: δ=7.48 (m, 2H), 7.35(m, 2H), 5.91(s, 1H); 
13CNMR (CDCl3) 165.3, 152.0, 136.6, 130.1, 129.6, 128.7, 121.3, 
82.9; IR (KBr‒disc) δmax: 3451, 3075, 2952, 2051, 1769, 1636, 
1497, 1419, 1289, 1231, 1027, 927, 826, 748, 720cm‒1
3,4‒Dichloro‒5‒(4‒fluoro‒phenyl)‒5H‒furan‒2‒one, 
Lactone C
Yield=79% mp: 74‒76oC; MS (APCI(+)): 212/213/214 (M+1), 
1HNMR (CDCl3) 250MHz: δ=7.46(m, 2H), 7.34 (m, 2H), 5.90(s, 1H); 
13CNMR (CDCl3) 165.0, 151.9, 136.4, 130.1, 129.6, 128.7, 121.3, 
82.7; IR (KBr‒disc) δmax: 3450, 3075, 2952, 2049, 1768, 1636, 
1497, 1419, 1289, 1027, 927, 826, 749, 719cm‒1.
Preparation of stage 2 products: pyrrolone synthesis
The general method was previously reported and 
the spectroscopic data are reported for a full SAR analysis and 
optimisation with respect to antineoplastic properties.
4‒Chloro‒5‒hydroxy‒1‒methyl‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 1
Yield=75%; mp: 146‒148oC; MS (APCI(+)): 193/195(M+1), 
224/226(M+) m/z; 1HNMR (DMSO‒d6)) 250 MHz: 7.29‒7.48 (m, 
5H), 6.49(s, 1H), 2.08 (s, 3H) 13CNMR (CDCl3) 168.1, 156.4, 134.1, 
129.4, 128.9, 126.2, 121.3, 92.6, 24.5ppm. IR (KBr‒disc): 3224, 
3110, 2952, 2820, 2617, 2375, 2339, 1975, 1697, 1605, 1453, 1438, 
1258, 1207, 1065, 992, 856, 764, 704cm‒1.
4‒Chloro‒5‒(4‒chloro‒phenyl)‒5‒hydroxy‒1‒
methyl‒1,5‒dihydro‒pyrrol‒2‒one 2
Yield=66%; mp: 179‒181oC; MS (APCI(+)): 227/229/231 (M+1), 
258/260/262(M+) m/z; 1HNMR (CDCl3) 250MHz: 7.31‒7.42 (m, 
4H), 6.06 (s, 1H), 4.56‒4.71 (bs, 1H), 2.60 (s, 3H) 13CNMR (CDCl3) 
167.8, 156.0, 135.5, 132.8, 129.1, 127.8, 121.6, 92.2, 24.4ppm. IR 
(KBr‒disc) 3429, 3102, 2970, 2932, 2857, 1677, 1611, 1494, 1475, 
1431, 1202, 1151, 1091, 988, 928, 811, 692cm‒1.
4‒Chloro‒5‒hydroxy‒1‒isopropyl‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 3
Yield=79%; mp: 163‒165oC; MS (APCI(+)): 193/195(M+1), 
252/254(M+) m/z; 1HNMR (CDCl3) 250MHz: 7.40‒7.51 (m, 5H), 
6.14 (s, 1H), 3.81 (bs, 1H), 3.42 (m, 1H), 1.33& 1.21 (m, 6H) 13C 
NMR (CDCl3) 167.5, 155.0, 135.0, 129.1, 128.5, 126.4, 122.4, 93.4, 
45.6, 21.1, 20.0ppm. IR (KBr‒disc) 3227, 2990, 2940, 2365, 2350, 
1956, 1693, 1615, 1456, 1428, 1247, 1131, 1072, 1009, 934, 847, 747, 
697cm‒1.
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4‒Chloro‒5‒(4‒chloro‒phenyl)‒5‒hydroxy‒1‒
isopropyl‒1,5‒dihydro‒pyrrol‒2‒one 4
Yield =69%; mp: 127‒130oC; MS (APCI(+)): 286/288/290 (M+) 
m/z; 1HNMR (CDCl3) 250MHz: 7.31(m, 4H), 6.06 (s, 1H), 3.33 (m, 
1H), 1.25&1.10 (m, 6H). 13CNMR (CDCl3) 167.1, 154.0, 136.7, 
133.4, 128.9, 128.0, 123.2, 92.9, 45.6, 20.1, 21.3ppm. IR (KBr‒disc) 
3272, 2978, 2927, 1691, 1614, 1496, 1429, 1384, 1352, 1249, 1096, 
1012, 936, 846, 801, 683cm‒1.
4‒Chloro‒1‒cyclopropyl‒5‒hydroxy‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 5
Yield=83%; mp: 177‒179oC; MS (APCI(+)): 193/195 (M+1), 
250/252 (M+) m/z; 1HNMR (CDCl3) 250MHz: δ= 7.41 (m, 5H), 6.09 
(s, 1H), 3.50 (m, 1H), 2.18 (m, 1H), 0.95& 0.38 (m, 4H); 13CNMR 
(CDCl3) 167.4, 154.8, 135.2, 129.2, 128.8, 126.1, 122.2, 93.5, 22.6, 
3.8, 5.1ppm. IR (KBr‒disc) 3416, 3260, 3105, 3011, 2363, 2338, 
1671, 1602, 1490, 1450, 1409, 1369, 1256, 1144, 1032, 939, 833, 
752, 702cm‒1.
4‒Chloro‒5‒(4‒chloro‒phenyl)‒1‒cyclopropyl‒5‒
hydroxy‒1,5‒dihydro‒pyrrol ‒2‒one 6
Yield=72%; mp: 169‒171oC; MS (APCI(+)): 284/286/288 (M+) 
m/z; 1HNMR (CDCl3) 250MHz: 7.22 (m, 4H), 5.97 (s, 1H), 3.98 (bs, 
1H), 1.76 (m, 1H), 0.24‒0.99 (m, 4H); 13CNMR (CDCl3) 165.8, 155.4, 
144.2, 133.7, 129.0, 127.7, 122.2, 91.7, 22.6 , 3.7, 5.2ppm. IR (KBr‒
disc) 3433, 3220, 3019, 2935, 2858, 1700, 1675, 1497, 1412, 1251, 
1209, 1144, 1089, 1015, 940, 844, 802, 679cm‒1.
4‒Chloro‒5‒hydroxy‒1‒isobutyl‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 7
Yield=85%; mp: 167‒169oC; MS (APCI(+)): 266/268 (M+) m/z; 
1HNMR (CDCl3) 250MHz: 7.38‒7.51 (m, 5H), 6.24 (s, 1H), 4.79 
(bs, 1H), 3.23&2.18 (m, 2H), 1.71 (m, 1H), 0.76 (m, 6H) 13CNMR 
(CDCl3) 168.5, 155.7, 137.1, 129.2, 128.7, 126.2, 121.7, 93.1, 47.6, 
27.5, 20.4ppm. IR (KBr‒disc) 3237, 3114, 2965, 2926, 2881, 2374, 
2343, 1675, 1614, 1460, 1416, 1299, 1251, 1202, 1150, 1072, 1027, 
878, 758, 696cm‒1.
4‒Chloro‒5‒(4‒chloro‒phenyl)‒5‒hydroxy‒1‒
isobutyl‒1,5‒dihydro‒pyrrol‒2‒one 8
Yield = 66%; mp: 155‒158oC; MS (APCI(+)): 300/302/304 (M+) 
m/z; 1HNMR (CDCl3) 250MHz: 7.30 (m, 4H), 6.19 (s, 1H), 3.13 (m, 
1H), 2.49 (m, 1H), 1.69 (m, 1H), 0.69 (t, J = 4.5 Hz, 6H) 13CNMR 
(CDCl3) 163.3, 156.3, 139.4, 134.8, 129.1, 127.7, 122.3, 95.0, 47.6, 
27.6, 20.4ppm. IR (KBr‒disc) 3426, 3252, 2964, 2850, 1684, 1406, 
1209, 1095, 817, 743, 703cm‒1.
4‒Chloro‒5‒(4‒ f luoro‒phenyl)‒5‒hydroxy‒1‒
isobutyl‒1,5‒dihydro‒pyrrol‒2‒one 9
Yield=76%; mp: 158‒159oC; MS (APCI(+)): 300/302/304 (M+) 
m/z; 1HNMR (CDCl3) 250MHz: 7.30 (m, 4H), 6.19 (s, 1H), 3.13 (m, 
1H), 2.49 (m, 1H), 1.69 (m, 1H), 0.69 (t, J = 4.5 Hz, 6H) 13CNMR 
(CDCl3) 163.3, 156.3, 139.4, 134.8, 129.1, 127.7, 122.3, 95.0, 47.6, 
27.6, 20.4ppm. IR (KBr‒disc) 3426, 3252, 2964, 2850, 1684, 1406, 
1209, 1095, 817, 743, 703cm‒1.
4‒Chloro‒1‒cyclopentyl‒5‒hydroxy‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 11
Yield=81%; mp: 180‒182oC; MS (APCI(+)): 278/280 (M+) m/z; 
1HNMR (CDCl3) 250MHz: δ= 7.51 (m, 5H), 6.08 (s, 1H), 4.87 (bs, 
1H), 3.59 (m, 1H), 1.99 (m, 2H), 1.81 (m, 4H), 1.46 (m, 4H); 13C 
NMR (CDCl3) 167.2, 155.0, 135.2, 129.1, 128.6, 126.5, 122.2, 93.3, 
54.3, 30.0, 28.8, 24.5, 24.4ppm. IR (KBr‒disc) 3220, 2961, 2877, 
2373, 2341, 1684, 1613, 1448, 1426, 1248, 1199, 1141, 1070, 934, 
850, 750, 701cm‒1.
4‒Chloro‒5‒(4‒chloro‒phenyl)‒1‒cyclopentyl‒5‒
hydroxy‒1,5‒dihydro‒pyrrol‒2‒one 12
Yield=73%; mp: 157‒159oC; MS (APCI(+)): 312/314/316 (M+) 
m/z; 1HNMR (CDCl3) 250MHz: δ= 7.42 (m, 4H), 6.03 (s, 1H), 4.99 
(bs, 1H), 3.51‒3.62 (m, 1H), 1.97‒2.19 (m, 2H), 1.68‒1.93 (m, 8H); 
13C NMR (CDCl3) 167.1, 154.8, 135.2, 133.9, 128.9, 128.0, 122.3, 
93.0, 54.3, 30.0, 28.9, 24.5ppm. IR (KBr‒disc) 3407, 3276, 2968, 
2922, 2883, 2379, 2339, 1691, 1491, 1429, 1367, 1249, 1203, 1092, 
1013, 932, 843, 787, 709cm‒1.
4‒Chloro‒1‒hexyl‒5‒hydroxy‒5‒phenyl‒1,5‒dihydro‒
pyrrol‒2‒one 13
Yield=51%; mp: 173‒175oC; MS (APCI(+)):294/296 (M+) m/z; 
1H NMR (CDCl3) 250MHz: 7.40 (m, 5H), 6.15 (s, 1H), 4.76 (bs, 1H), 
3.28 (m, 1H), 2.91 (m, 1H), 1.09‒1.59 (m, 8H), 0.78‒0.92 (t, J = 7.1 
Hz, 3H) 13C NMR (CDCl3) 168.0, 155.6, 134.9, 129.2, 128.7, 126.2, 
121.8, 93.0, 40.2, 31.3, 28.7, 26.8, 22.5, 14.0ppm. IR (KBr‒disc) 
3245, 2930, 2865, 1689, 1658, 1494, 1453, 1412, 1365, 1321, 1150, 
1069, 927, 753, 696 cm‒1.
4‒C h l o ro‒5‒ ( 4‒c h l o ro‒p h e ny l )‒1‒h ex y l‒5‒
hydroxy‒1,5‒dihydro‒pyrrol‒2‒one 14
Yield=49%; mp: 169‒172oC; MS (APCI(+)): 328/330/332 (M+) 
m/z; 1H NMR (CDCl3) 250MHz: 7.31(m, 4H), 6.15 (s, 1H), 3.24 (m, 
1H), 2.67 (m, 1H), 1.04‒1.69 (m, 8H), 0.74 (t, J = 6.3 Hz, 3H) 13C 
NMR (CDCl3) 165.8, 155.7, 140.8, 136.9, 129.1, 127.8, 91.6, 40.3, 
30.8, 29.1, 26.8, 22.6, 15.2ppm. IR (KBr‒disc) 3446, 2935, 2863, 
1698, 1413, 1252, 1200, 1138, 1092, 1013, 938, 846, 814, 702cm‒1.
4‒Chloro‒1‒cyclohexyl‒5‒hydroxy‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 15
Yield=57%; mp: 170‒172oC; MS (APCI(+)): 292/294 (M+) m/z; 
1HNMR (CDCl3) 250MHz: 7.26‒7.61 (m, 5H), 6.08 (s, 1H), 3.77 
(bs, 1H), 2.88 (m, 1H), 1.21‒2.07 (m, 10H); 13CNMR (CDCl3) 163.9, 
153.9, 135.0, 129.25, 128.9, 126.4, 122.9 , 96.0, 53.6, 32.8, 31.1, 29.8, 
26.2 , 24.2ppm. IR (KBr‒disc) 3440, 2924, 2858, 2355, 2344, 1641, 
1449, 1367, 1250, 1138, 1016, 996, 742, 695cm‒1.
4‒Chloro‒1‒(phenyl)‒5‒hydroxy‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 16
Yield=48%; mp: 168‒171oC; MS (APCI(+)): 314/316 (M+) m/z; 
1HNMR (CDCl3) 250MHz: δ=7.46 (m, 5H), 7.34 (m, 5H), 6.38 (s, 
1H), 3.68 (bs, 1H); 13CNMR (CDCl3) 168.9, 159.7, 136.9, 135.1, 
132.4, 129.9, 129.0, 126.9, 123.0, 122.3, 122.2, 93.5; IR (KBr‒disc) 
3517, 3357, 3114, 2840, 2674, 2361, 2342, 1678, 1607, 1464, 1412, 
1361, 1208, 1138, 1071, 988, 755, 700cm‒1.
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1‒Benzyl‒4‒chloro‒5‒hydroxy‒5‒phenyl‒1,5‒dihydro‒
pyrrol‒2‒one 17
Yield=71%; mp: 165‒167oC; MS (APCI(+)): 300/302 (M+) m/z; 
1HNMR (CDCl3) 250MHz: 7.36 (m, 5H), 7.24 (m, 5H), 6.08 (s, 1H), 
4.69 (m, 2H), 3.62 (bs, 1H); 13CNMR (CDCl3) 167.9, 155.9, 137.6, 
134.4, 129.3, 128.7, 128.4, 128.4, 127.3, 127.1, 126.4, 93.2, 43.4; IR 
(KBr‒disc) 3446, 3279, 3098, 2931, 2850, 2374, 2334, 1684, 1611, 
1456, 1413, 1349, 1276, 1205, 1128, 1051, 696cm‒1.
1‒Benzy l‒4‒ch loro‒5‒(4‒ch loro‒pheny l )‒5‒
hydroxy‒1,5‒dihydro‒pyrrol‒2‒one 18
Yield=59%; mp: 149‒152oC; MS (APCI(+)): 334/336/338 (M+) 
m/z; 1H NMR (CDCl3) 250MHz: δ= 7.33 (m, 4H), 7.16 (m, 5H), 6.09 
(s, 1H), 4.60 (m, 2H), 13CNMR (CDCl3) 167.6, 155.4, 137.5, 135.3, 
133.2, 129.1, 129.0, 128.9, 128.6, 128.4, 127.9, 127.4, 121.9, 92.6, 
43.2; IR (KBr‒disc) 3442, 2931, 2849, 2365, 2339, 1674, 1616, 1492, 
1406, 1349 1272, 1199, 1094, 1018, 817, 699cm‒1.
1‒Benzy l‒4‒ch loro‒5‒ (4‒ f l uoro‒pheny l )‒5‒
hydroxy‒1,5‒dihydro‒pyrrol‒2‒one 19
Yield = 59%; mp: 149‒152oC; MS (APCI(+)): 318/319/320 (M+) 
m/z; 1H NMR (CDCl3) 250MHz: δ= 7.32 (m, 4H), 7.14 (m, 5H), 6.10 
(s, 1H), 4.60 (m, 2H), 13CNMR (CDCl3) 167.5, 155.2, 137.2, 135.3, 
133.2, 129.0, 129.0, 128.6, 127.6, 128.4, 127.9, 127.4, 121.9, 92.6, 
43.2; IR (KBr‒disc) 3442, 2931, 2849, 2365, 2339, 1674, 1616, 1492, 
1406, 1349 1272, 1199, 1094, 1018, 817, 699cm‒1.
4‒Chloro‒5‒hydroxy‒5‒phenyl‒1‒((S)‒(‒)‒1‒phenyl‒
ethyl)‒1,5‒dihydro‒pyrrol‒2‒one 20
Yield=66%; mp: 162‒164oC; MS (APCI(+)): 314/316 (M+)m/z; 
1HNMR (CDCl3) 250MHz: δ= 7.44 (m, 7H), 7.08‒7.25 (m, 3H), 5.96 
(s, 1H), 4.16 (m, 1H), 3.37 (bs, 1H), 1.49 (m, 3H); 13CNMR (CDCl3) 
167.3, 154.3, 142.5, 134.7, 129.4, 128.7, 128.4, 127.7, 127.3, 126.4, 
123.0, 93.8, 53.5, 18.8ppm. IR (KBr‒disc) 3241, 2983, 2932, 2863, 
2366, 2347, 1686, 1661, 1614, 1494, 1456, 1425, 1356, 1258, 1202, 
1025, 931, 855, 755, 692cm‒1.
4‒Chloro‒5‒hydroxy‒5‒phenyl‒1‒((S)‒(‒)‒1‒phenyl‒
ethyl)‒1,5‒dihydro‒pyrrol‒2‒one 21
Yield=4%; MS (APCI(+)): 314/316 (M+) m/z; 1HNMR (CDCl3) 
250MHz: δ= 7.29‒7.53 (m, 7H), 6.95 (m, 3H), 6.08 (s, 1H), 4.78 (m, 
1H), 2.71 (bs, 1H), 1.63 (m, 3H).
4‒Chloro‒5‒hydroxy‒1‒phenethyl‒5‒phenyl‒1,5‒
dihydro‒pyrrol‒2‒one 22
Yield=89%; mp: 155‒158oC; MS (APCI(+)): 314/316 (M+) m/z; 
1HNMR (CDCl3) 250MHz: δ= 7.09‒7.53 (m, 10H), 6.20 (s, 1H), 
3.74 (m, 1H), 2.88‒3.29 (m, 3H), 2.65 (m, 1H); 13CNMR (CDCl3) 
168.0, 155.7, 139.0, 134.6, 129.4, 128.85, 128.84, 128.6, 126.6, 126.2 
, 121.8, 92.7, 41.9 , 34.6ppm. IR (KBr‒disc) 3433, 3246, 2929, 2366, 
2334, 1681, 1658, 1607, 1455, 1406, 1251, 1151, 1128, 1066, 931, 
753, 699cm‒1.
4‒Chloro‒5‒(4‒chloro‒phenyl)‒5‒hydroxy‒1‒
phenethyl‒1,5‒dihydro‒pyrrol‒2‒one 23
Yield=45%, mp: 145‒148oC; MS (APCI(+)): 348/350/352 (M+)
m/z; 1H NMR (CDCl3) 250MHz: δ= 7.22‒7.49 (m, 7H), 7.12‒7.18 
(m, 2H), 6.13 (s, 1H), 3.68 & 2.64 (m, 2H), 2.88 (m, 2H); 13C NMR 
(CDCl3) 250MHz: 167.7, 155.5, 138.8, 135.5, 133.3, 129.1, 128.8, 
128,7, 127.7, 126.7, 121.9, 92.3, 42.0, 34.5; IR (KBr‒disc) 3421, 
3228, 2925, 2848, 2370, 2338, 1684, 1658, 1606, 1461, 1406, 1248, 
1190, 1097, 935, 806, 697cm‒1.
4‒Chloro‒5‒(4‒ f luoro‒phenyl )‒5‒hydroxy‒1‒
phenethyl‒1,5‒dihydro‒pyrrol‒2‒one 24
Yield = 55%, mp: 147‒151oC; MS (APCI(+)): 332/334 (M+) 
m/z; 1H NMR (CDCl3) 250MHz: δ= 7.22‒7.49 (m, 7H), 7.12‒7.18 
(m, 2H), 6.13 (s, 1H), 3.68 & 2.64 (m, 2H), 2.88 (m, 2H); 13CNMR 
(CDCl3) 250MHz: 167.7, 155.5, 138.8, 135.5, 133.3, 129.1, 128.8, 
128,7, 127.7, 126.7, 121.9, 92.3, 42.0, 34.5; IR (KBr‒disc) 3421, 
3228, 2925, 2848, 2370, 2338, 1684, 1658, 1606, 1461, 1406, 1248, 
1190, 1097, 935, 806, 697cm‒1.
I‒CCK‒8 Radioligand cholecystokinin binding assay
CCK2 and CCK1 receptor binding assays were performed using 
standard receptor binding assays.24,25 Male guinea pig brain tissues 
were prepared according to the modified method described.28 
Pancreatic membranes were prepared as described and binding assays 
were carried out with L‒363, 260 as standard.29 
Isolated tissue preparations
Male Sprague Dawley rats, weighing 200‒250g were used and 
all animal care and experimental protocols adhered to the relevant 
laws and guidelines of the institution. The animals were housed under 
standard conditions of temperature (25°C) with unrestricted access 
to food and water. Experimental details are reported in using Tyrode 
solution and CCK‒5, as agonist at increasing concentrations in Tyrode 
solution Figure 2. Test molecules and lorglumide as standard, were 
added to the organ bath with a 10minute incubation period prior to the 
addition of CCK.
Molecular modeling
Protein structures such as 1HZN for the cholecystokinin receptor 
and 1L4T for the gastrin receptor were downloaded from the protein 
data bank in pdb format. Guest‒host‒interactions were analysed with 
Autodock Vina and after convergence was achieved, the docking 
results were visualized with Designer studio 4.5. 
In vivo study
Xenograft study in NSG mice
Human cancer cells were grown in DMEM supplemented 
with 10% FBS at 37oC in an incubator with 5%CO2. For xenograft 
implantation the relevant cells were harvested and viable cells were 
determined by trypan blue exclusion. A cell suspension in growth 
medium was prepared and this cell suspension in growth medium 
was implanted subcutaneously in NSG mice Figure 3. 1million cells 
were transplanted subcutaneously per mouse. Once tumours reached 
100mm3, the animals were randomized within the respective cell 
line and treated orally. Animals were sacrificed at the end of the 
experiment or when the tumours reached over 1500mm3 or when the 
animals lost over 20% body weight. All experiments were performed 
in compliance with the relevant laws and institutional guidelines and 
the institutional bioethics committee has approved the experiments.
Statistical methods
ANOVA was the selected one‒way analysis of variance and a 
difference was indicated as significant when the difference was found 
p<0.05.
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Figure 2 CCK standards & pyrazolone based CCK1 antagonist derived from 2(5H)‒ furanones.
Figure 3 Synthesis of 5‒hydroxy‒5‒aryl‒pyrrol‒2‒ones from mucochloric 
acid.
Results and discussion
Chemistry
5‒arylated dichloro‒2(5H)‒furanones A‒C were synthesised from 
mucochloric acid (Scheme 1). Mucochloric acid is commercially 
available under oxidising conditions with hydrochloric acid from 
furfural. Furfural is available from biomass by hydrolysis with strong 
acids. Mucochloric acid was reacted into the stage 1 intermediates 
with benzene, chlorobenzene and fluorobenzene Figure 4. The arene 
or haloarene acted as reagent and solvent at RT under the development 
of hydrogen chloride gas. Depending on the scale of the reaction 
the exothermic properties of the electrophilic substitution reaction 
required cooling with ice. For the Friedel‒ Crafts‒Acylation the best 
catalyst and Lewis acid is granulated aluminium chloride on a small 
scale. However, on a larger scale aluminium chloride was replaced 
by trifluoroborane in THF to closely control the exothermic nature of 
the reaction Figure 5A & 5B. The 5‒arylated 3,4‒dichloro‒2 (5H)‒
furanones A, B & C (Stage 1 intermediates) reacted in ether with 
alkyl‒ and aryl alkyl amines into N‒alkylated hydroxyl‒pyrrolones 
1‒24 ( Stage 2 products ). Diethylether or MTB ether is essential 
to furnish the stage 2 products in high yields under mild conditions 
and 2 step synthesis is outlined in Scheme 1. All pyrrolones 1‒24 
are present in the 5‒membered ring form, as a hydroxyl‒pyrrolone 
and not in the ring opened keto form. The 5‒arylated 2(5H)‒
furanones reacted selectively in the ester position ‒ a lactone was 
converted into a lactam‒and no attack in the 4‒position, Michael 
position, was observed. Previously, using a polar solvent, such as 
dimethylformamide, DMF, the IPSO substitution in the 4‒position 
was described for pseudo‒ esters.30 In terms of reaction mechanism 
a ring‒opening ring‒closure mechanism is proposed here for the 
formation of the hydroxy‒pyrrolones. It is supposed, that the first step 
in the reaction sequence, is a ring opening of the stage 1 intermediate 
with amide formation. Subsequently, the keto form of the acyclic 
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amide was converted in situ into a lactam under the elimination of 
hydrogen chloride. During this process, involving an achiral arylated 
ketoform, the stereo chemical information is lost and experimentally 
a racemic mixture is found of the R‒and S‒enantiomeric forms. A 
50:50 ratio of both enantiomers was found by chiral HPLC in solution 
in methanol for lactam 7 and 22 Figure 6. The phenylfuranones were 
evaluated previously as anticancer agents based on their alkylating 
properties and not as a targeted chemotherapeutic agent. Overall the 
desired N‒alkylated 5‒phenyl pyrrolones 1‒24 were obtained in only 
a 2 stage process as mostly white and crystalline materials.31
Figure 4 Overview of selected molecules.
Figure 5(A) Drug receptor interactions of isobutyl lactam 7 and the CCK1 
receptor.
Figure 5(B) Docking of CCK antagonist lactam 22 into the CCK2 receptor.
Figure 6 Log concentration‒ response curves obtained in the presence of 
CCK‒8S alone and CCK‒8S in the presence of lactame 24 (PNB‒101).
SAR optimisation
The first step was to screen for potent binding affinity and to 
identify a CCK1 or CCK2‒selective ligand for subsequent m
‒1and 
in vivo evaluation. Using radiolabelled iodinated cholecystokinin, 
inhibition of binding was determined for all test molecules and the 
IC
50
 are outlined in Table 1. Lorglumide served as CCK1 standard 
and L‒365,260 was used as CCK2 standard. Hydroxy‒pyrrolones 
containing an N‒methyl group, lactame 1‒2, showed no binding 
affinity and the formation of homologues resulted in micromolar 
binding affinity for the iso‒propyl group, as seen in lactame 3 and 4. 
Ring closure on the N‒substituent, from isopropyl to cyclo‒propyl 
resulted in a loss of activity (lactame 5, 6) and the ring enlargement 
from a 3‒membered to a 5‒membered ring system (entry 11‒12) 
resulted in a similar binding affinity. Changing N‒propyl into an 
N‒butyl resulted in a major increase of binding activity and the 
overall best substituent was found iso‒butyl on the central nitrogen 
atom, derivative 7. The introduction of a halogen atom into the para‒
position of the phenyl group resulted in an increase of binding affinity 
as observed for lactam 8 and lactam 9. The iso‒butyl group on the N‒
atom produced the best overall ligand, with CCK1 selectivity and the 
IC
50
 was reduced significantly for t‒butyl derivative 10. The n‒pentyl 
analogue was formed in very low yields and the n‒hexyl lactams 13, 
14 clearly lost binding affinity and the same was observed for the 
cyclohexyl derivative 15. A phenyl substituent on the N in pyrrolone 
16, resulted in a loss of activity (>10µM). The N‒benzylated derivative 
pyrrolone 17, resulted in non‒selective CCK‒ligand. A chlorine 
atom, changed the binding affinity marginally for the lactam 18 and 
the introduction of fluorine for lactam 19, resulted in a significantly 
improved binding affinity, thus providing us with a potent mixed CCK 
antagonist. The introduction of a chiral amine, such as methyl benzyl 
amine provided diastereoisomers (Entry 20, 21), which were separated 
by column chromatography, and both stereoisomers occurred a lower 
affinity than the parent benzyl derivative 17. The introduction of a 
single spacer, such as a methylene group, resulted a highly selective 
CCK2 ligand 22, which is 450times selective for the CCK2/gastrin 
receptor. Chlorination in the p–position, lactam 23, did not enhance 
binding affinity any further, but a fluorine atom enhanced binding 
affinity towards for the gastrin receptor to an IC
50
 as low as 13nM. 
Thus, lactam 24, was identified a SAR optimised molecule, possibly 
as a result of an additional hydrogen bond of the fluorine atom with 
the gastrin receptor Table 1.
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Table 1 CCK binding affinity expressed in IC50 in micromolar using iodinated 
hot CCK8 as radioligands with cortex and pancreatic membranes; N=3
Lactam X= R= CCK1[mM] CCK2[mM]
1 H Methyl‒ 2.5±0.2 >10
2 Cl Methyl‒ 2.0±0.2 >10
3 H Isopropyl‒ 0.2±0.02 0.9±0.03
4 Cl Isopropyl‒ 0.3±0.04 3.7±0.4
5 H Cyclopropyl‒ 7.5±0.4 >10
6 Cl Cyclopropyl‒ 4.0±0.2 >10
7 H Isobutyl‒ 0.020±0.01 1.2±0.3
8 Cl Isobutyl‒ 0.008±0.01 0.4±0.2
9 F Isobutyl‒ 0.012±0.01 0.75±0.2
10 H t‒butyl‒ 0.12±0.22 0.9±0.03
11 H Cyclopentyl‒ 0.36±0.03 0.84±0.2
12 Cl Cyclopentyl‒ 2.5±0.03 >10
13 H Hexyl‒ 4.5±0.3 >10
14 Cl Hexyl‒ 3.6±0.3 >10
15 H Cyclohexyl‒ 2.5±0.3 >10
16 H Phenyl‒ >10 >10
17 H Benzyl‒ 0.85±0.03 0.020±0.005
18 Cl Benzyl‒ 0.51±0.004 0.022±0.004
19 F Benzyl‒ 0.11±0.004 0.012±0.004
20 H Methylbenzyl‒ 0.6±0.04 0.021±0.01
21 H Methylbenzyl‒ 0.42±0.03 0.21±0.05
22 H Phenylethyl‒ >10 0.022±0.002
23 Cl Phenylethyl‒ >10 0.030±0.001
24 F Phenylethyl‒ >10 0.013±0.001
Lorglumide ‒ ‒ 0.17±0.01 >10
L‒356,260 ‒ ‒ 0.25±0.01 0.003±0.001
Overall, the introduction of alkyl groups, most preferred an 
isobutyl‒group, provided a CCK1 selective antagonist 9, which 
was the selected development candidate PNB‒028 for colon and 
pancreatic cancer. The N‒benzylated pyrrolone 17 displayed a non‒
selective receptor binding profile and the modification of the spacer 
between the N‒atom of the central pyrrolone template (Lactam 22 and 
24) from benzyl to phenyl‒ethyl provided us with potent and selective 
CCK2 receptor antagonists Figure 2. These selected molecules were 
evaluated in vitro using tissue based assays. Molecular modelling 
was performed to rationalise the drug receptor interactions for the 
parent molecules. Molecular modelling studies were performed for 
isobutyl derivative with the CCK1 receptor Figure 3. The isobutyl 
group of the ligand 7 interacted with a hydrophobic cave of the 
receptor, centred at Ala‒14. The carbonyl group in the 2‒position 
bond via hydrogen binding towards the CCK receptor with Arg‒9 and 
the N‒atom of the lactam interacted with Glu‒17. The 5‒hydroxy‒
group of the ligand displayed interactions with of Asn‒6, while the 
phenyl group has no interaction with tryptophan or phenylalanine. 
Pi‒alkyl interactions only may explain the small increase in binding 
affinity of the chlorinated analogue compared with PNB‒081, based 
on interaction with Leu‒29 and Ile‒28. If the para phenyl position 
is not blocked by the chorine atom, most interestingly, the proposed 
metabolite can interact with the CCK2 receptor. It is supposed that 
lactam 7, is hydroxylated in the para phenyl position by P450 and 
this metabolite may interact with the CCK2 receptor via His 122 
interaction. Most interestingly hydroxylation may also enhance CCK1 
affinity due to interactions with Arg 9. The docking of lactam 22 
into the CCK2 receptor is outlined in and some key interactions are 
highlighted for one final pose of minimal energy Figure 7A & 7B. 
The 5‒hydroxy group of the central pyrrolone template interacted via 
hydrogen binding with the N group of Trp114. The phenyl group of 
the N‒phenylethyl‒ side chain bound to the aromatic indole system of 
Trp114 and electron withdrawing groups may enhance these aromatic 
interactions. The lipophilic pocket allowed principally a wide range 
of substituents, but only phenyl and not cyclo‒hexyl could be realised 
synthetically. The 5‒phenyl group of the pyrrolone template bound 
via Ile 184 and Leu 133, based on van der Waals interactions and 
not aromatic interactions. The introduction of electron withdrawing 
groups, such as halogen atoms, is therefore only marginally enhancing 
binding affinity. The Fluorinated derivative 24 may feature hydrogen 
binding with His144 and this extra interaction may explain the 
improved affinity of lactam 24 over 23. Overall, the observed binding 
affinity and the predicted interaction based on molecular modelling 
interaction correlated well for the cholecystokinin and the gastrin 
receptor.
Figure 7(A) Effect of PNB‒101 in nude mice‒ bearing subcutaneous lung 
NCI H727 tumour xenografts. Values are expressed as Mean ±SEM of each 
group. Note G4, 300mg/kg PNB‒101 for 14 days, Cycle 2: 200mg/kg and 
Cisplatin 7.5mg/kg.
Figure 7(B) Change in body weight of nude mice treated with PNB‒101 
bearing subcutaneous lung NCIH 727 tumour xeno graft. Values are expressed 
as Mean ±SEM of 6 animals in each group. Note: G4, 300mg/kg PNB‒101 for 
14 days, Cycle 2: 200mg/kg and Cisplatin 7.5mg/kg.
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Pharmacology
Isolated tissue preparations
A clear SAR was obtained for the entire series of molecules, 
outlined in Table 1, with respect to gastrin selectivity. The fluorinated 
lactame 24 was selected for in vitro evaluation using isolated tissue 
preparations. Using the isolated rat duodenum preparation, stable 
amplitude was generated for pentagastrin and a reduction of this 
amplitude was observed dose dependently for lactam 24, which is 
outlined in Figure 4. This assay represented a fast and efficient way to 
screen for CCK antagonists using classical isolated tissue preparations. 
The selected lactam acted as much lower concentrations than L‒365, 
260, the CCK2 standard. It appeared Figure 4 that the effect of the 
antagonist 24 in the rat duodenum assay is insurmountable and an 
irreversible inhibitor is ideal for the development of antineoplastic 
agents. The function of the fluorine atom in lactam 24 was found dual 
to firstly enhance binding affinity and secondly to block metabolism 
of the molecules in the para–phenyl position, thus enhancing oral 
bioavailability. From 24 molecules in table 1 the phenyl‒ethyl 
substituent was identified a privileged structure. Together with the 
isobutyl and benzyl derivatives a series of close analogues were 
screened in vitro using cell based assays. 
Cell based in vitro assay
CCK antagonists are associated with an array of therapeutic 
applications, but the focus of our research programme was to provide 
a non‒toxic, orally available CCK antagonist for the treatment of 
cancers. The antineoplastic properties of selected NCE and standard 
CCK antagonists, such as L‒365,260 (CC1H) and lorglumide (CCK1) 
were subsequently investigated, using a range of CCK associated 
cancer cell lines. It was screened for an inhibitor of viability in 
certain CCK related cancer cell lines using the MTT assay. MCF‒7 
and MB‒231 are humane breast cancer cell lines and MCF‒7 did not 
express CCK receptors. For MCF‒7 no activity was found in vitro 
for the test molecules and standards. The triple resistant cell line 
MDA‒MB‒231 showed inhibition in vitro in our experiments and in 
xenografts in nude mice, antineoplastic activity was associated with 
the gastrin releasing peptide receptor independent from oestrogen. 
MAC 13 and MAC16 cell lines are murine colon cancer cell lines. 
MAC16 is resistant to alkylating agents and has a high expression of 
the CCK receptor In line with the receptor expression, activity was 
found for lactame 7 and 9, but the IC
50
 for benzylated lactame.32,33 
19 was 4 times higher. Previously we reported activity for lactame 
9 on pancreatic cancer cell lines. Most interestingly, no other CCK 
antagonist, such as L‒365, 260 or lorglumide was found active for 
this cell line, which is, when transplanted into mice lethal within 7 
days. Based on this key difference between the known agents and our 
inhibitors, it may be concluded, that the unsurmountable irreversible 
properties of the antagonists are blocking only the proliferation of 
cell growth. The anticancer activity of the agents is not limited to GI 
cancers. The cytotoxicity of 2 selected human lung cancer cell lines 
was shown initially for lactam 19. The mixed CCK antagonist 19 
showed a low nanomolar activity in cell based assays. Lung cancer is 
associated with overexpression of CCK2 receptors.
34 NCI‒H322 was 
derived in 1981 from a primary bronchioalveolar carcinoma of the 
lung from a 52 year old male. Cells of this non‒small cell carcinoma 
cell line produce tumours in athymic mice. H‒727, the second human 
lung cancer cell line in our programme, was studied earlier for the 
gastrin CCK2 antagonist CI‒988 and proliferation was promoted by 
CCK
8S
 and gastrin. Based on binding affinity, results from isolated 
tissue preparations and the experience of fluorinated molecules having 
favourable bioavailability, lactam 24 was submitted to xenograft 
analysis using the humane H‒727 cell line Table 2. 
Table 2 Cytotoxicity assay, IC50 of selected examples against a variety of 
breast, GI and lung cancer cell lines. IC50 values are based on inhibition of 
viability in the MTT assay
Breast cancer Colon cancer Lung cancer
IC50 [nM] MCF‒7
MDA‒
MB‒231
MAC13 MAC16
NCI‒
H322
H‒727
L‒365,260 >5000 941±88 >5000 >5000 441±54 841±88
Lorglumide >5000 >5000 421±11 861±22 >5000 >5000
Lactam 7 >5000 >5000 536±32 96±25 >1000 >1000
Lactam 9 >5000 275±11 508±35 76±20 231±21 341±21
Lactam 19 >5000 76±20 >1000 326±29 31±2 38±6
Lactam 22 >5000 121±11 >1000 >1000 13±4 45±4
Lactam 24 >5000 231±21 >1000 >1000 46±7 72±8
Animal studies in mice
Xenograft in vivo lung cancer study 
The fluorinated phenyl ethyl pyrrol 24 has had promising in vitro 
activity on cell lines in the nanomolar range. Lactam 24, went into 
preclinical development as PNB‒101 and was selected for further in 
vivo studies using nude mice and the results are outlined in Figure 5.
The transplanted lung tumour cell line proliferated exponentially 
and 100mg/kg reduced growths significantly (40% inhibition, day 24) 
and a further reduction was found dose dependently for the 200mg/kg 
dose and the antineoplastic effect appeared saturated for the 300mg/
kg dose (64%, Day 24). Cis‒platin served as standard and killed the 
tumour, when treated early until resistance was observed on day 27. 
When cis‒platin was applied to an established tumour, no inhibitory 
effect on tumour growth was observed at all in cycle 2 for the group 4.
The acute toxicity was assessed as loss of body weight and 
cis‒platin showed a clear reduction of body weight, in contrast 
PNB‒101, which increased body weight at all doses, not significantly 
different from the control. No toxicity of this targeted experimental 
chemotherapeutic agent PNB‒101 was found and no signs of 
resistance as for cisplatin were observed for the entire period in the 
xenograft study. The importance of the gastrin receptor is not limited 
to lung cancer, but also linked with liver cancer and other gastrin 
related cancers, such as the cancer of the stomach. With PNB‒028 
(cholecystokinin antagonist) and PNB‒101 (gastrin antagonist) 
targeted chemo‒selective agents will become available for a range 
of cancers, which were historically characterised by origin, and now, 
will become treatable based on a specific common endocrine growth 
factor.35
Conclusion
These novel pyrrol‒ones showed a good inhibition for CCK 
and gastrin related cancers. PNB‒101 was identified as best gastrin 
related anticancer agent and entered early preclinical development 
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(PK analysis and membrane penetrations studies). Thus, 2 potent 
molecules PNB‒028 and PNB‒101 are available from fluoro‒benzene 
and furfural via the same stage 1 intermediate, making them readily 
available molecules with a great therapeutic potential. In vitro SAR 
evaluation has already indicated future therapeutic areas, in addition 
to lung cancer, such as triple resistant breast cancers, which are still 
an unmet therapeutic need. The known CNS activity of our CCK 
antagonists may be of additional therapeutic benefit in treating cancer 
associated diseases, such as pain, anxiety and depression.
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